---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-26-000003"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T11:00:17.976961+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M

## Summary
- Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.
- Full year 2025 test volumes ~1.5M (+1% YoY): hereditary cancer +7%, mental health +6%, prenatal -4%.
- FY 2026 revenue guidance $860-880M (midpoint +6% vs FY25 prelim midpoint).
- FY 2026 adjusted gross margin guidance 68-69%; adjusted EBITDA $37-49M (midpoint +43% vs prior FY25 guide).
- Formal Q4/FY 2025 earnings call scheduled for February 2026.

## SEC filing metadata
- accession: 0000899923-26-000003
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992326000003/0000899923-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992326000003/mygn-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-26-000003
- JSON: https://secwatch.observer/filing/0000899923-26-000003.json
- Plain text: https://secwatch.observer/filing/0000899923-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.